News Releases

Archives: Search / 2018 / 2017 / 2016 / 2015 / 2014 / 2013 / 2012

201120102009200820072003

2008 Archives

Dec 31, 2008

Nektar Therapeutics today announced that it has successfully closed the divestiture of specific Nektar pulmonary delivery assets, technology, and intellectual property to Novartis for $115 million...

More
Nov 6, 2008

Nektar Therapeutics today announced that it has repurchased 32%, or $100.0 million, of its outstanding convertible debt for approximately 48 cents on the dollar, for a total purchase price of...

More
Oct 27, 2008

Nektar Therapeutics announced that it will host an R&D Day for investors and analysts at the InterContinental Hotel in New York on Wednesday, November 12, 2008, beginning at 12:00 p.m. Eastern...

More
Oct 24, 2008
Active metabolite concentrations of NKTR-102 significantly more sustained in between doses than possible with irinotecan

Nektar Therapeutics today reported positive Phase 1 data for its lead proprietary oncology product candidate, NKTR-102 (PEG-irinotecan). The data were presented at the 20th EORTC-NCI-AACR...

More
Oct 23, 2008

Nektar Therapeutics will announce its financial results for the third quarter ended September 30, 2008 on Thursday, November 6, 2008, after the close of U.S.-based financial markets. Howard Robin,...

More
Oct 23, 2008

Nektar Therapeutics announced today that positive preclinical data for NKTR-105 (PEG-docetaxel) was presented at the 2008 EORTC-NCI-AACR (European Organization for Research and Treatment of...

More
Oct 21, 2008

(11:00 PM PT, Oct. 20) -- Nektar Therapeutics today announced that Novartis AG has agreed to acquire from Nektar specific pulmonary delivery assets, technology, and intellectual property for $115...

More
Oct 7, 2008

Nektar Therapeutics President and CEO Howard W. Robin is scheduled to present at the upcoming Natixis Bleichroeder Second Annual Hidden Gems Conference in New York at the Waldorf-Astoria Hotel on...

More
Sep 16, 2008

Nektar Therapeutics' President and Chief Executive Officer, Howard W. Robin, is scheduled to present at the upcoming UBS 2008 Global Life Sciences Conference in New York at the Grand Hyatt New...

More
Aug 6, 2008

Nektar Therapeutics today announced the appointment of Randall Moreadith, M.D., Ph.D., to the position of Senior Vice President of Drug Development and Chief Development Officer effective August...

More
Aug 6, 2008

Nektar Therapeutics today announced the company's financial results for the second quarter and six-months ended June 30, 2008. Cash, cash equivalents, and short-term investments were $373.9...

More
Jul 30, 2008

Nektar Therapeutics will announce its financial results for the second quarter ended June 30, 2008 on Wednesday, August 6, 2008, after the close of U.S.-based financial markets. Howard Robin,...

More
Jun 2, 2008
Phase 2 Study for NKTR-102 Will Target Newly-Identified K-Ras Mutated Oncogene Population in Patients with Advanced Colorectal Cancer

Nektar Therapeutics today announced an expanded Phase 2 development plan for NKTR-102 (PEG-irinotecan). The company will target newly-characterized colorectal cancer patients with K-Ras mutated...

More
Jun 2, 2008

Nektar Therapeutics announced new positive data today from a Phase 1 clinical study for NKTR-102 (PEG-irinotecan) in advanced cancer patients whose tumors had progressed on other therapies....

More
May 30, 2008

Nektar Therapeutics will host a meeting and Webcast on Monday, June 2, 2008 at 6:30 PM Central Time to discuss the company's lead oncology program, NKTR-102 (PEG-irinotecan). The Webcast will...

More
May 22, 2008

Nektar Therapeutics announced today that Bharatt Chowrira, Ph.D., J.D. has joined the Company as Chief Operating Officer and Head of the PEGylation Business Unit. His responsibilities include...

More
May 19, 2008
- Bayer together with Nektar Therapeutics present preliminary Phase II data for the adjunctive treatment of pneumonia in intubated and mechanically-ventilated patients

Bayer HealthCare together with Nektar Therapeutics , today presented positive preliminary Phase II data on their unique drug-device combination Amikacin Inhale at the American Thoracic Society...

More
May 16, 2008
Nektar's Technology Enables First-Ever PEGylation of a Small Molecule with Demonstrated Therapeutic Activity

Nektar Therapeutics announced initial results today from a Phase 1 study of NKTR- 102, PEGylated irinotecan. The data shows significant anti-tumor activity in patients with refractory solid...

More
May 12, 2008

Nektar Therapeutics highlighted today that its proprietary PEGylation technology is used in the novel therapeutic, Hematide™, a synthetic, peptide-based erythropoiesis-stimulating agent that is...

More
May 7, 2008

Nektar Therapeutics announced today the company's financial results for the first quarter ended March 31, 2008. Cash, cash equivalents, and short-term investments were $412.6 million at March 31,...

More
May 7, 2008
U.S. Patent Encompassing Tobramycin Inhalation Powder and Other Aminoglycoside Antibiotics Issued to Nektar

Nektar Therapeutics today announced that the U.S. Patent and Trademark Office has issued Patent No. 7,368,102, which covers compositions and methods for creating and delivering Tobramycin...

More
May 7, 2008

New Phase 1 clinical trial results for NKTR-118 (oral PEG-naloxol) were presented by Nektar Therapeutics this week at the Annual Meeting of the American Pain Society (APS) in Tampa, Florida. In...

More
Apr 30, 2008

Nektar Therapeutics will announce its financial results for the first quarter ended March 31, 2008 on Wednesday, May 7, 2008, after the close of U.S.-based financial markets. Howard Robin,...

More
Apr 23, 2008
Cimzia® marks the first FDA approval of a PEGylated Fab' fragment of a humanized anti-TNF-alpha antibody

The U.S. Food and Drug Administration (FDA) approved UCB's Cimzia® (certolizumab pegol) for reducing the signs and symptoms of Crohn's disease and maintaining clinical response in adult patients...

More
Apr 14, 2008

Positive preclinical data was presented by Nektar Therapeutics this week for its lead oncolytic candidate, NKTR-102 (PEG-irinotecan), which demonstrated enhanced anti-tumor activity in a mouse...

More
 

print email rss
 
 
Site Map Privacy Terms of Use Compliance Policy Trademarks Site Users Guide